Abstract
The discovery of novel leads and their subsequent optimization into development compounds is the key element in any drug discovery process. During the last several years, substantial efforts have been dedicated to the establishment of high-throughput screening technologies (HTS) (Houston and Banks 1997). Computer tools have been developed to drive robotic systems to fully automate and speed up the experimental testing along with a sophisticated selection of compounds used in the various screening assays. Testing entire libraries within weeks or even days is now feasible. However, initial euphoria that was pronouncing the end of any rational or knowledge-based approach to lead discovery has been superseded by a more realistic view, mainly as a result of the considerable costs involved and disappointingly low hit rates (Lahana 1999).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abbate F, Supuran CT, Scozzafava A, Orioli P, Stubbs MT, Klebe G (2002) The sulfonamide group is an ideal anchor for potent human carbonic anhydrase inhibitors: evidence from a comparative crystallographic study. J Med Chem 45: 3583–3587
Allen FH, Davies JE, Galloy JJ, Johnson O, Kennard O, Macrae CF, Mitchell EM, Mitchell GF, Smith JM, Watson DG (1991) The development of verion-3 and version-4 of the Cambridge Structural Database system. J Chem Info Comput Sci 31: 187–204
Anderson AC, O’Neil RH, Surti TS, Stroud RM (2001) Approaches to solving the rigid receptor problem by identifying a minimal set of flexible residues during ligand docking. Chem Biol 8: 445–457
Bergner A, Gunther J, Hendlich M, Klebe G, Verdorsk M (2002) Use of Relibase for retrieving complex 3D interaction patterns including crystallographic packing effects. Nucl Acid Sci 61: 99–110
Block P (2002) Diploma thesis, Univ. Marburg
Blundell T, Jhoti H, Abell C (2002) High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Discov 1: 45–54
Bode W, Chen Z, Bartels K, Kutzbach C, Schmidt-Kastner G, Bartunik H (1983) Refined 2 Angstroms X-Ray crystal structure of porcine pancreatic kallikrein A, a specific trypsin-like serine proteinase. Crystallization, structure determination, crystallographic refinement, Structure and its comparison with bovine trypsin. J Mol Biol 164: 237–282
Böhm HJ, Klebe G (1996) What can we learn from molecular recognition in protein—ligand complexes for the design of new drugs? Angew Chem Int Ed Engl 35: 2588–2614
Bossemeyer D, Engh RA, Kinzel V, Ponstingl H, Huber R (1993) Phosphotransferase and substrate binding mechanism of the cAMP- dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 A structure of the complex with Mn2+ adenylyl imidodiphosphate and inhibitor peptide PKI(5–24) EMBO J 12: 849–859
Broder S, Venter JC (2000) Sequencing the entire genomes of free-living organisms: the foundation of pharmacology in the new millennium. Annu Rev Pharmacol Toxicol 40: 97–132
Burley SK, Almo SC, Bonanno JB, Capel M, Chance MR, Gaasterland T, Lin D, Sali A, Studier FW, Swaminathan S (1999) Structural genomics: beyond the Human Genome Project. Nat Genet 23: 151–157
Chegwidden WR, Edwards Y, Carter N (2000) The Carbonic anhydrases — new horizons. Birkhäuser Verlag, Basel
Claussen H, Buning C, Rarey M, Lengauer T (2001) FlexE: efficient molecular docking considering protein structure variations. J Mol Biol 308: 377–395
Coll M, Guasch A, Aviles FX, Huber R (1991) Three-dimensional structure of porcine procarboxypeptidase B: a structural basis of its inactivity. EMBO J 10: 1–9
Divne C, Stahlberg J, Reinikainen T, Ruohonen L, Pettersson G, Knowles JK, Teen TT, Jones TA (1994) The three-dimensional crystal structure of the catalytic core of cellobiohydrolase I from Trichoderma reesei. Science 265: 524–528
Dramburg I (2003) PhD thesis Univ. Marburg
Drews J (2000) Drug discovery: a historical perspective. Science 287: 1960–1964
Gerber PR, Müller K (1995) MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry. J Comput Aided Mol Des 9: 251–268
Grüneberg S, Wendt B, Klebe G (2001) Subnanomolar inhibitors from computer screening: A model study using human carbonic anhydrase II. Angew Chem Int Ed 40: 389–393
Grüneberg S, Stubbs MT, Klebe G (2002) Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation. J Med Chem 45: 3588–3602
Gulick AM, Song H, Endow SA, Rayment I (1998) X-ray crystal structure of the yeast Kar3 motor domain complexed with Mg.ADP to 2.3 A resolution. Biochemistry 37: 1769–1776
Günther J, Bergner A, Hendlich M, Verdonk M, Klebe G (2003) Utilizing structural knowledge in drug design strategies — applications using Relibase. J Mol Biol (in press)
Hakansson K, Carlsson M, Svensson AL, Liljas A (1992) Structure of native and apo carbonic anhydrase II and structure of some of its anion-ligand complexes. J Mol Biol 227: 1192–1204
Hemm K, Aberer K, Hendlich M (1995) Constituting a receptor-ligand information base from quality-enriched data ISMB 3: 170–178
Hendlich M (1998) Databases for protein—ligand complexes. Acta Crystallogr D Biol Crystallogr 54: 1178–1182
Hendlich M, Günther J, Bergner A, Verdonk M, Klebe G (2003) Relibase — design and development of a database for comprehensive analysis of protein—ligand interactions. J Mol Biol (in press)
Hol W, Wierenga RK (1984) The a-helix dipole and the binding of phosphate groups of coenzymes and substrates by proteins. In: Horn AS, De Ranter CJ (eds) X-ray crystallography and drug design. Clarendon Press, Oxford, pp 151–168
Houston JG, Banks M (1997) The chemical-biological interface: developments in automated and miniaturised screening technology. Curr Opin Biotechnol 8: 734–740
Kador PF, Kinoshita JH, Sharpless NE (1985) Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. J Med Chem 28: 841–849
Kim C-Y, Chandra PP, Jain A, Christianson DW (2001) Fluoroaromaticfluoroarmatic interactions between inhibitors bound in the crystal lattice of human carbonic anhydrase II. J Am Chem Soc 123: 9620–9627
Klaholz BP, Mitschler A, Belema M, Zusi C, Moras D (2000) Enantiomer Discrimination Illustrated by high Resolution Structures of the Human Nuclear Receptor hRAR. Proc Nat Acad Sci 97: 6322–6327
Lahana R (1999) How many leads from HTS? Drug Discov Today 4: 447–448
Lam PY, Jadhav PK, Eyermann CJ, Hodge CN, Ru Y, Bacheler LT, Meek JL, Otto MJ, Rayner MM, WongYN, et al (1994) Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 263: 380–384
Lander ES, Linton LM, Binen B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland J, Kann L, Lehoczky J, LeVine R, McEwan P, McKernan K, Meldrim J, Mesirov JP, Miranda C, Morris W, Naylor J, Raymond C, Rosetti M, Santos R, Sheridan A, Sougnez C, Stange-Thomann N, Stojanovic N, Subramanian A, Wyman D, Rogers J, Sulston J, Ainscough R, Beck S, Bentley D, Burton J, Clee C, Carter N, Coulson A, Deadman R, Deloukas P, Dunham A, Dunham I, Durbin R, French L, Grafham D, Gregory S, Hubbard T, Humphray S, Hunt A, Jones M, Lloyd C, McMurray A, Matthews L, Mercer S, Milne S, Mullikin JC, Mungall A, Plumb R, Ross M, Shownkeen R, Sims S, Waterston RH, Wilson RK, Hillier LW, McPherson JD, Marra MA, Mardis ER, Fulton LA, Chinwalla AT, Pepin KH, Gish WR, Chissoe SL, Wendl MC, Delehaunty KD, Miner TL, Delehaunty A, Kramer JB, Cook LL, Fulton RS, Johnson DL, Minx PJ, Clifton SW, Hawkins T, Branscomb E, Predki P, Richardson P, Wenning S, Slezak T, Doggett N, Cheng JF, Olsen A, Lucas S, Elkin C, Uberbacher E, Frazier M, et al (2001) Initial sequencing and analysis of the human genome. Nature 409: 860–921
Martin JL, Begun J, Schindeler A, Wickramasinghe WA, Alewood D, Alewood PF, Bergman DA, Brinkworth RI, Abbenante G, March DR, Reid RC, Fair-lie DP (1999) Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease. Biochemistry 38: 7978–7988
Mikol V, Papageorgiou C, Borer X (1995) The role of water molecules in the structure-based design of (5-hydroxynorvaline)-2-cyclosporin: synthesis, biological activity, and crystallographic analysis with cyclophilin A. J Med Chem 38: 3361–3367
Muller-Dieckmann HJ, Schulz GE (1995) Substrate specificity and assembly of the catalytic center derived from two structures of ligated uridylate kinase. J Mol Biol 246: 522–530
Poornima CS, Dean PM (1995) Hydration in drug design. 1. Multiple hydrogen-bonding features of water molecules in mediating protein—ligand interactions. J Comput Aided Mol Des 9: 500–512
Rost B (1998) Marrying structure and genomics. Structure 6: 259–263
Rubin GM, Yandell MD, Wortman JR, Miklos GLG, Nelson CR, Hariharan IK, Fortini ME, Li PW, Apweiler R, Fleischmann W, Cherry JM, Henikoff S, Skupski MP, Misra S, Ashburner M, Birney E, Boguski MS, Brody T, Brokstein P, Celniker SE, Chervitz SA, Coates D, Cravchik A, Gabrielian A, Galle RF, Gelbart WM, George RA, Goldstein LS, Gong F, Guan P, Harris NL, Hay BA, Hoskins RA, Li J, Li Z, Hynes RO, Jones SJ, Kuehl PM, Lemaitre B, Littleton JT, Morrison DK, Mungall C, O’Farrell PH, Pickeral OK, Shue C, Vosshall LB, Zhang J, Zhao Q, Zheng XH, Zhong F, Zhong W, Gibbs R, Venter JC, Adams MD, Lewis S (2000) Comparative genomics of the eukaryotes. Science 287: 2204–2215
Schmitt S, Hendlich M, Klebe G (2001) From structure to function: a new approach to detect functional similarity among proteins independent from sequence and fold homology. Angew Chem Int Ed 40: 3141–3144
Schmitt S, Kuhn D, Klebe G (2002) A new method to detect related function among proteins independent of sequence and fold homology. J Mol Biol 323: 387–406
Schnecke V, Swanson CA, Getzoff ED, Tainer JA, Kuhn LA (1998) Screening a peptidyl database for potential ligands to proteins with side-chain flexibility. Proteins 33: 74–87
Smith GM, Alexander RS, Christianson DW, McKeever BM, Ponticello GS, Springer JP, Randall WC, Baldwin JJ, Habecker CN (1994) Positions of His-64 and a bound water in human carbonic anhydrase II upon binding three structurally related inhibitors. Protein Sci 3: 118–125
Stahlberg J, Divne C, Koivula A, Piens K, Claeyssens M, Teeri TT, Jones TA (1996) Activity studies and crystal structures of catalytically deficient mutants of cellobiohydrolase I from Trichoderma reesei. J Mol Biol 264: 337–349
Supuran CT, Scozzafava A (2000) Carbonic anhydrase inhibitors and their therapeutic potential. Exp Opin Ther Patents 10: 575–601
Supuran CT, Scozzafava A (2001) Carbonic anhydrase inhibitors. Curr Med Chem Imm Endoc Metab Agents 1: 61–97
Surgrue MF (2000) Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Progr Ret Eye Res 19: 87–112
Tranter R, Read JA, Jones R, Brady RL (2000) Effector sites in the three dimensional structure of mammalian sperm beta-acrosin structure. Struct Fold Des 8: 1179–1188
Urzhumtsev A, Tete-Favier F, Mitschler A, Barbanton J, Barth P, Urzhumtseva L, Biellmann JF, Podjarny A, Moras D (1997) A `specificity’ pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Structure 5: 601–612
Wang H, Ben-Naim A (1996) A possible involvement of solvent-induced interactions in drug design. J Med Chem 39: 1531–1539
Xue Y, Liljas A, Jonsson BH, Lindskog S (1993) Structural analysis of the zinc hydroxide — Thr 199 — Glu 106 hydrogen-bond network in human carbonic anhydrase II. Proteins: Struct Funct Genet 10: 93–106
Zhang Y, Bond CS, Bailey S, Cunningham ML, Fairlamb AH, Hunter WN (1996) The crystal structure of trypanothione reductase from the human pathogen Trypanosoma cruzi at 2.3 A resolution. Protein Sci 5: 52–61
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Klebe, G. (2003). From Structure to Recognition Principles: Mining in Crystal Data as a Prerequisite for Drug Design. In: Waldmann, H., Koppitz, M. (eds) Small Molecule — Protein Interactions. Ernst Schering Research Foundation Workshop, vol 42. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-05314-0_8
Download citation
DOI: https://doi.org/10.1007/978-3-662-05314-0_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-05316-4
Online ISBN: 978-3-662-05314-0
eBook Packages: Springer Book Archive